Law360 (subscription) The ANDA Strides and Agila filed aiming to the market a 0.3 percent concentration gatifloxacin opthalmic solution purports to show that the defendants' proposed product would be bioequivalent to Allergan's Zymar, and refers to Allergan's own new drug ...
Patent Docs 6,333,045 ("Aqueous Liquid Pharmaceutical Composition Comprised of Gatifloxacin ," issued December 25, 2001) following a Paragraph IV certifications as part of defendants' filing of an ANDA to manufacture a generic version of Allergan's Zymar® (0.3 w/v ...
